MA56001A - Formes de sel cristallin d'un inhibiteur de kinase - Google Patents
Formes de sel cristallin d'un inhibiteur de kinaseInfo
- Publication number
- MA56001A MA56001A MA056001A MA56001A MA56001A MA 56001 A MA56001 A MA 56001A MA 056001 A MA056001 A MA 056001A MA 56001 A MA56001 A MA 56001A MA 56001 A MA56001 A MA 56001A
- Authority
- MA
- Morocco
- Prior art keywords
- kinase inhibitor
- salt forms
- crystalline salt
- crystalline
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856404P | 2019-06-03 | 2019-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56001A true MA56001A (fr) | 2022-04-06 |
Family
ID=69160360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056001A MA56001A (fr) | 2019-06-03 | 2019-12-12 | Formes de sel cristallin d'un inhibiteur de kinase |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20230052703A1 (enExample) |
| EP (1) | EP3976587B1 (enExample) |
| JP (1) | JP7579281B2 (enExample) |
| KR (1) | KR102826380B1 (enExample) |
| CN (1) | CN113939503B (enExample) |
| AU (1) | AU2019449809B2 (enExample) |
| BR (1) | BR112021024300A2 (enExample) |
| CA (1) | CA3139148A1 (enExample) |
| CL (1) | CL2021003205A1 (enExample) |
| CO (1) | CO2021017343A2 (enExample) |
| CR (1) | CR20210616A (enExample) |
| DO (1) | DOP2021000236A (enExample) |
| ES (1) | ES3008963T3 (enExample) |
| GE (2) | GEP20247655B (enExample) |
| IL (1) | IL288484A (enExample) |
| MA (1) | MA56001A (enExample) |
| MX (1) | MX2021014773A (enExample) |
| PE (1) | PE20220962A1 (enExample) |
| PH (1) | PH12021553020A1 (enExample) |
| SG (1) | SG11202111978VA (enExample) |
| WO (1) | WO2020247019A1 (enExample) |
| ZA (1) | ZA202108034B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| KR102828472B1 (ko) * | 2018-12-13 | 2025-07-03 | 엑셀리시스, 인코포레이티드 | 키나아제 억제제의 결정질 형태 및 염 형태 |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
| US20250368606A1 (en) | 2021-12-22 | 2025-12-04 | Exelixis, Inc. | Crystalline forms and salt forms of a kinase inhibitor |
| CN116751161A (zh) * | 2023-06-28 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | 喹啉类化合物及其制备方法、药物组合物及医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| CA2604238C (en) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| ES2598530T3 (es) * | 2010-07-14 | 2017-01-27 | Betta Pharmaceuticals Co., Ltd. | Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| US20180009758A1 (en) * | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| MA48776A (fr) * | 2017-05-26 | 2020-04-08 | Exelixis Inc | Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation |
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| KR102828472B1 (ko) * | 2018-12-13 | 2025-07-03 | 엑셀리시스, 인코포레이티드 | 키나아제 억제제의 결정질 형태 및 염 형태 |
| CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2019
- 2019-12-12 MX MX2021014773A patent/MX2021014773A/es unknown
- 2019-12-12 EP EP19836340.0A patent/EP3976587B1/en active Active
- 2019-12-12 BR BR112021024300A patent/BR112021024300A2/pt unknown
- 2019-12-12 WO PCT/US2019/065980 patent/WO2020247019A1/en not_active Ceased
- 2019-12-12 US US17/616,124 patent/US20230052703A1/en active Pending
- 2019-12-12 GE GEAP201915849A patent/GEP20247655B/en unknown
- 2019-12-12 KR KR1020217041796A patent/KR102826380B1/ko active Active
- 2019-12-12 JP JP2021571744A patent/JP7579281B2/ja active Active
- 2019-12-12 PE PE2021002015A patent/PE20220962A1/es unknown
- 2019-12-12 CR CR20210616A patent/CR20210616A/es unknown
- 2019-12-12 PH PH1/2021/553020A patent/PH12021553020A1/en unknown
- 2019-12-12 ES ES19836340T patent/ES3008963T3/es active Active
- 2019-12-12 AU AU2019449809A patent/AU2019449809B2/en active Active
- 2019-12-12 GE GEAP202415849A patent/GEAP202415849A/en unknown
- 2019-12-12 CN CN201980097028.2A patent/CN113939503B/zh active Active
- 2019-12-12 SG SG11202111978VA patent/SG11202111978VA/en unknown
- 2019-12-12 CA CA3139148A patent/CA3139148A1/en active Pending
- 2019-12-12 MA MA056001A patent/MA56001A/fr unknown
-
2021
- 2021-10-20 ZA ZA2021/08034A patent/ZA202108034B/en unknown
- 2021-11-17 DO DO2021000236A patent/DOP2021000236A/es unknown
- 2021-11-28 IL IL288484A patent/IL288484A/en unknown
- 2021-12-02 CL CL2021003205A patent/CL2021003205A1/es unknown
- 2021-12-16 CO CONC2021/0017343A patent/CO2021017343A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021553020A1 (en) | 2023-08-23 |
| JP7579281B2 (ja) | 2024-11-07 |
| ES3008963T3 (en) | 2025-03-25 |
| EP3976587A1 (en) | 2022-04-06 |
| EP3976587B1 (en) | 2024-12-04 |
| BR112021024300A2 (pt) | 2022-01-11 |
| AU2019449809B2 (en) | 2026-02-05 |
| SG11202111978VA (en) | 2021-11-29 |
| CN113939503A (zh) | 2022-01-14 |
| CN113939503B (zh) | 2024-05-07 |
| IL288484A (en) | 2022-01-01 |
| KR102826380B1 (ko) | 2025-06-26 |
| AU2019449809A1 (en) | 2021-12-16 |
| DOP2021000236A (es) | 2022-04-18 |
| CA3139148A1 (en) | 2020-12-10 |
| GEAP202415849A (en) | 2024-03-11 |
| KR20220016117A (ko) | 2022-02-08 |
| PE20220962A1 (es) | 2022-06-10 |
| US20230052703A1 (en) | 2023-02-16 |
| EP3976587C0 (en) | 2024-12-04 |
| JP2022535072A (ja) | 2022-08-04 |
| WO2020247019A1 (en) | 2020-12-10 |
| CO2021017343A2 (es) | 2022-01-17 |
| GEP20247655B (en) | 2024-08-26 |
| ZA202108034B (en) | 2025-02-26 |
| CR20210616A (es) | 2022-03-22 |
| CL2021003205A1 (es) | 2022-09-30 |
| MX2021014773A (es) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56001A (fr) | Formes de sel cristallin d'un inhibiteur de kinase | |
| MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
| EP3947361A4 (en) | SALT AND CRYSTAL FORM OF A FAK INHIBITOR | |
| EP3924352A4 (en) | CRYSTALLINE FORMS OF AN RSK INHIBITOR | |
| MA53226A (fr) | Sel et formes cristallines d'omecamtiv mecarbil | |
| EP3870178A4 (en) | Crystalline forms of mnk inhibitors | |
| MA52493A (fr) | Sels d'un inhibiteur de fgfr | |
| MA55614A (fr) | Formes cristallines d'inhibiteur de pyridazinone trpc | |
| MA54526A (fr) | NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta | |
| EP3619208C0 (en) | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | |
| SG11202107225SA (en) | Crystalline form of a cdk inhibitor | |
| EP3472168A4 (en) | CRYSTALLINE FORMS OF A TRIAZOLOPYRIMIDINE COMPOUND | |
| EP3807279A4 (en) | PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERINE | |
| MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
| IL289929A (en) | Crystal forms of cd73 inhibitor | |
| EP3897660A4 (en) | NEW CRYSTALLINE FORMS OF AN NRTTI COMPOUND | |
| EP3873463A4 (en) | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | |
| EP3829551A4 (en) | CRYSTALLINE EPINEPHRIN MALONATE SALT | |
| MA54638A (fr) | Formes cristallines d'un stimulateur de sgc | |
| SG11202102110PA (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
| EP4019496A4 (en) | SALT AND CRYSTAL FORM OF A COMPOUND WITH AGONISTIC ACTION ON S1P5 RECEPTOR | |
| EP3996707A4 (en) | CRYSTALLINE FORMS OF PLASMACALLICREIN INHIBITORS | |
| MA53561A (fr) | Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k) | |
| EP3896063A4 (en) | SALT INES SYK INHIBITORS AND CRYSTALLINE FORM THEREOF | |
| EP3849964A4 (en) | CRYSTALLINE FORMS OF A QUINAZOLE COMPOUND AND ITS HYDROCHLORIDE SALTS |